Preliminary results of a first-in-human trial for a new CAR T-based treatment targeting two different sites on glioblastoma tumors result in dramatic, but transient, reductions in tumor size.

From Marcela V. Maus and colleagues, first author Bryan D. Choi. Featured in the Mass. General Hospital Bench Press Blog and the Harvard Gazette.